Skip to main content
SpringerLink
Log in

Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Observational studies of the effect of beta-interferon (IFNβ) on accumulation of fixed disability in relapsing remitting multiple sclerosis (RRMS) in clinical practice have been difficult to interpret due to bias. The aim of this study of 175 RRMS patients was to use Bayesian analysis to establish whether IFNβ attenuates disability relative to a cohort of matched historical control subjects from the Sylvia Lawry Centre for MS Research. A sensitivity analysis was based on a range of prior probability distributions for IFNβ efficacy derived from a published meta-analysis of randomised controlled trials (RCTs) of IFNβ, and the data were interpreted both unmodified and using variance inflation and point estimate bias correction; the corrected data interpreted in the light of the most likely prior probability distribution yielded a 95 % posterior credible interval for the odds ratio of accumulation of fixed disability after two years of IFNβ therapy of 0.52, 0.94. It is concluded that two years of IFNβ therapy for RRMS reduces accumulation of fixed disability in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. IFNβ Multiple Sclerosis Study Group, the University of British Columbia MS/MRI analysis group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial.Neurology 45:1277–1285

    Google Scholar 

  2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294

    Article  CAS  PubMed  Google Scholar 

  3. PRISMS study group (1998) Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet 352:1498–1504

    Article  Google Scholar 

  4. Rabeneck L, Viscoli CM, Horwitz RI (1992) Problems in the conduct and analysis of randomised clinical trials: are we getting the right answers to the wrong questions? Arch Intern Med 152:507–512

    Article  CAS  PubMed  Google Scholar 

  5. Vandenbroucke JP (2004) When are observational studies as credible as randomised trials? Lancet 363:1728–1731

    Article  PubMed  Google Scholar 

  6. Ashby D, Hutton JL, McGee MA (1993) Simple Bayesian analyses for case-control studies in cancer epidemiology. Statistician 42:385–397

    Article  Google Scholar 

  7. Bergamaschi R, Berzuini C, Romani A, Cosi V (2001) Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 189:13–21

    Article  CAS  PubMed  Google Scholar 

  8. Parmar MKB, Ungerleider RS, Simon R (1996) Assessing whether or not to perform a randomised clinical trial. J Natl Cancer Inst 88:1645–1651

    Article  CAS  PubMed  Google Scholar 

  9. Poser CM, Paty DW, Scheinberg LC, McDonald WI, Davis FA, Ebers GC, et al. (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13:227–231

    Article  CAS  PubMed  Google Scholar 

  10. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    CAS  PubMed  Google Scholar 

  11. Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M, et al. (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 52:400–406

    Article  CAS  PubMed  Google Scholar 

  12. Fillipini G,Munari L, Incorvaia B, Ebers GC, Polman C, D’Amico R, et al. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545–552

    Article  Google Scholar 

  13. Spiegelhalter DJ, Freedman LS, Parmar MKB (1994) Bayesian approaches to randomised trials. J Roy Stat Soc Series A 157:357–387

    Google Scholar 

  14. O'Rourke KET, Hutchinson M (2005) Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 11:46–50

    Article  PubMed  Google Scholar 

  15. Carra A, Onaha P, Sinay V, Alverez F, Luetic G, Bettinelli R, et al. (2003) A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 10:671–676

    Article  CAS  PubMed  Google Scholar 

  16. Rio J, Tintore M, Nos C, Tellez N, Galan I, Montalban X (2005) Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 252:795–800

    Article  CAS  PubMed  Google Scholar 

  17. Arbizu T, Alverez-Cermeno JC, Decap G, Fernandez O, Uria DF, Garcia Merino A, et al. (2000) Interferon beta- 1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain, Acta Neurol Scand 102:209–217

    Article  CAS  PubMed  Google Scholar 

  18. Trojano M, Liguori M, Paolicelli D, Bosco Zimatore G, De Robertis F, Avolio C, et al. (2003) Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 9:451–457

    Article  CAS  PubMed  Google Scholar 

  19. Dubois BD,Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, et al. (2003) Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 74:946–949

    Article  CAS  PubMed  Google Scholar 

  20. Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, et al. (2003) A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74:1689–1692

    Article  CAS  PubMed  Google Scholar 

  21. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419–1428

    Article  PubMed  Google Scholar 

  22. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T (2005) Changes in the ascertainment of multiple sclerosis.Neurology 65:1066–1070

    Article  CAS  PubMed  Google Scholar 

  23. Thygesen P (1953) The course of multiple sclerosis. Copenhagen: Rosenkilde and Baggen

  24. Liu C, Blumhardt LD (2000) Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 68:450–457

    Article  CAS  PubMed  Google Scholar 

  25. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. (1999) The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 122:1941–1950

    Article  PubMed  Google Scholar 

  26. Wolpert RL, Mengersen KL (2004) Adjusted likelihoods for synthesizing empirical evidence from studies that differ in quality and design: effects of environmental tobacco smoke. Stat Sci 19:450–471

    Article  Google Scholar 

  27. Lilford RJ, Braunholtz D (1996) The statistical basis of public policy: a paradigm shift is overdue. BMJ 313:603–607

    CAS  PubMed  Google Scholar 

  28. Schulz KF, Chalmers I, Grimes DA, Altman DG (1994) Assessing the quality of randomisation from report of controlled trials published in obstetrics and gynaecology journals. JAMA 272:125–128

    Article  CAS  PubMed  Google Scholar 

  29. Sacks H, Chalmers T, Smith H (1982) Randomised versus historical controls for clinical trials. Am J Med 72:233–240

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Statistics, Trinity College, Dublin, Ireland

    C. Walsh

  2. Dept. of Neurology, St. Vincent’s University Hospital, Dublin 4, Ireland

    K. O'Rourke &  M. Hutchinson

Authors
  1. K. O'Rourke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Hutchinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Hutchinson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Rourke, K., Walsh, C. & Hutchinson, M. Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol 254, 1547–1554 (2007). https://doi.org/10.1007/s00415-007-0584-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-007-0584-x

Key words

Search

Navigation